Literature DB >> 17923842

Cell-penetrating peptide for enhanced delivery of nucleic acids and drugs to ocular tissues including retina and cornea.

Leslie N Johnson1, Siobhan M Cashman, Rajendra Kumar-Singh.   

Abstract

As in other organ systems, gene and drug delivery to ocular tissues such as the retina and cornea is hampered by inefficient penetration of therapeutic molecules across the plasma membrane. We describe the use of a novel peptide for ocular delivery (POD) with protein transduction properties, for delivery of small and large molecules across the plasma membrane. POD enters cells within 5 minutes in a temperature dependent manner. POD can compact and deliver plasmid DNA, achieving transgene expression in >50% of human embryonic retinoblasts. Delivery of small interfering RNA (siRNA) duplexes to cells using POD, allowed for silencing of transgene expression by >50%. POD could also be used to deliver quantum dots in vitro and in vivo. Upon ocular delivery, POD rapidly entered neural retina and localized to retinal pigment epithelium (RPE), photoreceptor, and ganglion cells. Additionally, POD was able to enter corneal epithelium, sclera, choroid, and the dura of the optic nerve via topical application. POD also functions as a bacteriostatic, a useful property for a carrier of molecules to post mitotic neural ocular tissues.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17923842      PMCID: PMC4145720          DOI: 10.1038/sj.mt.6300324

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  30 in total

1.  Ability of the Tat basic domain and VP22 to mediate cell binding, but not membrane translocation of the diphtheria toxin A-fragment.

Authors:  J Wesche; S Olsnes
Journal:  Biochemistry       Date:  2001-04-10       Impact factor: 3.162

2.  Is VP22 nuclear homing an artifact?

Authors:  M Lundberg; M Johansson
Journal:  Nat Biotechnol       Date:  2001-08       Impact factor: 54.908

3.  Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake.

Authors:  Jean Philippe Richard; Kamran Melikov; Eric Vives; Corinne Ramos; Birgit Verbeure; Mike J Gait; Leonid V Chernomordik; Bernard Lebleu
Journal:  J Biol Chem       Date:  2002-10-30       Impact factor: 5.157

4.  Intercellular trafficking of adenovirus-delivered HSV VP22 from the retinal pigment epithelium to the photoreceptors--implications for gene therapy.

Authors:  Siobhan M Cashman; Sonia L Sadowski; David J Morris; Jeanne Frederick; Rajendra Kumar-Singh
Journal:  Mol Ther       Date:  2002-12       Impact factor: 11.454

5.  Firm sets sights on gene silencing to protect vision.

Authors:  Erika Check
Journal:  Nature       Date:  2004-08-19       Impact factor: 49.962

6.  Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs.

Authors:  J Kelder; P D Grootenhuis; D M Bayada; L P Delbressine; J P Ploemen
Journal:  Pharm Res       Date:  1999-10       Impact factor: 4.200

Review 7.  Endophthalmitis associated with intravitreal injections.

Authors:  Janie Ho; John I Loewenstein
Journal:  Int Ophthalmol Clin       Date:  2007

8.  Escherichia coli endophthalmitis after trans-scleral resection of uveal melanoma.

Authors:  A Balestrazzi; M A Blasi; S Primitivo; E Balestrazzi
Journal:  Eur J Ophthalmol       Date:  2002 Sep-Oct       Impact factor: 2.597

9.  Evidence of protein transduction but not intercellular transport by proteins fused to HIV tat in retinal cell culture and in vivo.

Authors:  Siobhan M Cashman; David J Morris; Rajendra Kumar-Singh
Journal:  Mol Ther       Date:  2003-07       Impact factor: 11.454

Review 10.  Endogenous bacterial endophthalmitis: a 17-year prospective series and review of 267 reported cases.

Authors:  Timothy L Jackson; Susannah J Eykyn; Elizabeth M Graham; Miles R Stanford
Journal:  Surv Ophthalmol       Date:  2003 Jul-Aug       Impact factor: 6.048

View more
  44 in total

Review 1.  Nanoparticles for retinal gene therapy.

Authors:  Shannon M Conley; Muna I Naash
Journal:  Prog Retin Eye Res       Date:  2010-05-07       Impact factor: 21.198

2.  Probing potassium channel function in vivo by intracellular delivery of antibodies in a rat model of retinal neurodegeneration.

Authors:  Dorit Raz-Prag; William N Grimes; Robert N Fariss; Camasamudram Vijayasarathy; Maria M Campos; Ronald A Bush; Jeffrey S Diamond; Paul A Sieving
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-28       Impact factor: 11.205

3.  Corneal Penetrating Elastin-Like Polypeptide Carriers.

Authors:  Eric M George; Fakhri Mahdi; Omar C Logue; Grant G Robinson; Gene L Bidwell
Journal:  J Ocul Pharmacol Ther       Date:  2015-12-16       Impact factor: 2.671

4.  Intracellular delivery of proteins into mouse Müller glia cells in vitro and in vivo using Pep-1 transfection reagent.

Authors:  Minhua H Wang; Laura J Frishman; Deborah C Otteson
Journal:  J Neurosci Methods       Date:  2008-11-17       Impact factor: 2.390

Review 5.  Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy.

Authors:  A Guzman-Aranguez; P Loma; J Pintor
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

Review 6.  Gene delivery to cornea.

Authors:  Jinsong Hao; S Kevin Li; Winston W Y Kao; Chia-Yang Liu
Journal:  Brain Res Bull       Date:  2009-06-26       Impact factor: 4.077

Review 7.  Barriers for retinal gene therapy: separating fact from fiction.

Authors:  Rajendra Kumar-Singh
Journal:  Vision Res       Date:  2008-06-18       Impact factor: 1.886

8.  The potential of nanomedicine therapies to treat neovascular disease in the retina.

Authors:  Krysten M Farjo; Jian-Xing Ma
Journal:  J Angiogenes Res       Date:  2010-10-08

9.  A poly(ethylene) glycolylated peptide for ocular delivery compacts DNA into nanoparticles for gene delivery to post-mitotic tissues in vivo.

Authors:  Sarah Parker Read; Siobhan M Cashman; Rajendra Kumar-Singh
Journal:  J Gene Med       Date:  2010-01       Impact factor: 4.565

Review 10.  Peptide-mediated cellular delivery of oligonucleotide-based therapeutics in vitro: quantitative evaluation of overall efficacy employing easy to handle reporter systems.

Authors:  S D Laufer; T Restle
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.